Plain-English translation of NCT07690436 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing whether special eye imaging—similar to photos your eye doctor might take—can detect signs of transthyretin amyloid cardiomyopathy (ATTR-CM), a serious heart condition caused by abnormal protein deposits. Researchers want to see if looking at the retina (the back of your eye) might help doctors spot this disease early, without needing more invasive tests like heart biopsies or surgery.
Currently, diagnosing this heart condition often requires painful biopsies or specialized cardiac imaging. If doctors could use simple, non-invasive eye imaging to screen for this disease, they could identify and treat patients much earlier, potentially improving outcomes and making diagnosis easier and less risky.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have eye imaging performed—specifically retinal photographs and optical coherence tomography (OCT) scans, which are like taking detailed pictures of the back of your eye. The study lasts up to 90 days from when you enroll. You'll be in one of two groups: either people with confirmed amyloid heart disease or people with heart failure but without amyloid disease. The eye imaging itself is quick, painless, and non-invasive.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States